This article has Open Peer Review reports available.
Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer
© Ellberg and Olsson; licensee BioMed Central Ltd. 2011
Received: 8 September 2010
Accepted: 28 November 2011
Published: 28 November 2011
The association between lobular breast cancer and family history is not clear. The aim of the study was to possibly identifying new hereditary patterns predisposing for cancer in the different histopathologic subtypes of breast cancer, with focus on patients with lobular breast cancer and cancer in their first degree relatives.
In 1676 consecutive breast cancer patients detailed family history of cancer was related to histopathologic subtype of breast cancer.
Patients with lobular breast cancer were found to be significantly positively associated with having a father diagnosed with cancer, OR 2.17 (95% confidence interval (CI) 1.37-3.46). The finding persisted after excluding breast cancer in the family. Ductal breast cancer was associated with having a mother diagnosed with cancer. There was a significant association between lobular breast cancer and having a father with prostate cancer, OR 2.4 (CI 1.1-5.3). The occurrence of having a father with prostate cancer for lobular breast cancer patients was higher in the younger patient group, OR 2.9 (CI 1.1-7.8), and was still high but lost statistical significance in the older patient group, OR 1.9 (CI 0.5-7.4). The association between lobular breast cancer and a father remained significant after excluding fathers with prostate cancer, OR 1.94 (CI 1.20-3.14). Other commonly occurring tumor types in the father included sarcoma and leukemia.
We propose that lobular breast cancer is associated with having a father diagnosed with cancer, most commonly prostate carcinoma. Since the association remained after excluding family history of breast cancer, the association seems independent of classical breast cancer heredity. The association with a father diagnosed with cancer also remained after removing prostate cancer, indicating an independence from prostate cancer as well. The reason for this association is genetically unclear, but could involve sex-specific imprinting.
Risk factors, both genetic and environmental differ between the histopathological subtypes of breast cancer, one example is parity. It has been shown that increased parity reduced the risk for all subtypes with the exception of medullary breast cancer . Another risk factor, ever-use of HRT is associated with an increased risk of lobular breast cancer . In hereditary breast cancer, patients with BRCA1 -associated breast cancer are often hormone receptor negative and is more often of the medullary type, whereas patients with BRCA2 -associated breast cancer have a mixture of receptor negative and positive tumors and histopathologies .
The aim of the study was to further investigate the relationship between patients with different histopathological subtypes of breast cancer and cancer in their first degree relatives to possibly identify new hereditary patterns predisposing for cancer. We focused our study on lobular breast cancer since it is the second most common specified breast cancer subtype and not as well studied as ductal breast cancer. Many studies tend to focus more on molecular groups and as a supplement to them we focused our study on the classical histopathologic subtypes as a base for our study. Lobular breast cancer is the second most common histopathological subtype of breast cancer usually comprising between 5-15% of all cases [6–8]. Previous associations between lobular breast cancer and family history of cancer have been found, especially an association to family history of breast cancer in first degree relatives [9–12]. The familial association of lobular breast cancer could mainly be due to patients with BRCA2 mutation or the occurrence of hereditary diffuse gastric cancer . However, there is a need for further studies of familial cancer patterns in lobular breast cancer, comparing different histopathological types or molecular subtypes.
The 1676 breast cancer patients included in this study were all patients seen by one physician between 1st of January in 1980 and 1st of January in 2009. Using a standardized questionnaire filled out by the physician, information regarding previous family history of cancer was obtained, as well as reproductive and hormonal factors. The additional information concerning date of diagnosis, histopathological subtype, tumor biologic factors (including estrogen receptor (ER) and progesterone receptor (PR) status) was collected from pathological reports and hospital records. Pathological slides were not reexamined, but the diagnosis determining treatment was used. Recurrence of cancer, death and confirmation of the diagnosis on the relatives was retrieved from the Regional Cancer registry and census registry, and information regarding germline mutations was obtained from the Oncogenetic high-risk registry. Follow up was performed until 1st of January 2009. Informed consent was obtained from all patients. Ethical approvals for this study were obtained by the Ethical review board at Lund University, reference nr: 110/92 and 108/93.
All statistical analyses were performed using SPSS© 17.0. Only pure histopathological subtypes were used. Mixed, rare types and those breast cancer cases where the histopathological subtype was only known to be adenocarcinoma were grouped as "Others" and used as a reference group. Known mutation carriers were excluded from all analyses (n = 19). For all analyses, two-sided p-values ≤ 0.05 was considered statistically significant. Odds Ratios (OR) were estimated with 95% confidence intervals (CI). Because of the exploratory nature of this study no adjustment for multiple testing was made, and all results need to be validated in a different material.
Power analysis was made for ductal and lobular breast cancer. Actual sample size was used for each calculation. The significance level was set to 0.05, and the power to 0.80. For father with cancer the smallest detectable OR for ductal breast cancer was 2.016, and lobular breast cancer 3.436. For mother with cancer the smallest detectable OR for ductal breast cancer was 1.774, and lobular breast cancer it was 3.213. Excluding cases with breast cancer, the smallest detectable OR for ductal breast cancer was 2.176, and for lobular breast cancer 4.629.
Each histopathological tumor type was studied separately in a logistic regression model in relation to the occurrence of cancer in fathers, mothers, brothers and sisters (y/n), no family history of breast cancer, horizontal and vertical family history of breast cancer (y/n), ever-use of HRT (y/n), number of children (linear) and age at diagnosis (linear). A second analysis was performed in a similar manner, but excluding cases with a family history of breast cancer.
In a separate regression model histologic subtype of breast cancer was related to having a father diagnosed with cancer (y/n), ER-positivity (y/n), PR-positivity (y/n), horizontal and vertical family history of breast cancer (y/n) and age at diagnosis (linear). An analysis similar to this was performed where cases with a family history of breast cancer was excluded.
A third logistic regression model was used in which lobular breast cancer was related to first degree relatives with cancer (y/n), both including and excluding cases with breast cancer diagnoses in mothers and sisters.
In the last logistic regression model having a father with prostate cancer was related to ductal and lobular breast cancer (y/n) and age at diagnosis (y/n) in three variants; including all in the first, only patients younger the 60 years of age in the second, and patients equal to or older than 60 years of age in the third model. In a fourth model prostate cancer in father was excluded.
Binomial tests were performed by using the number of individuals in each branch of the family and comparing males with cancer to females with cancer.
Description of the population based patient material
Age at diagnosis: median(range)
Number of cases:
Age at diagnosis:
Cancer in 1° relatives:
No family history of cancer
-not including bc
- all diagnoses
- not including bc
Unknown family history
Family history of bc:
No family history of bc
Vertical family history
Horizontal family history
Cousin family history
Ever-use of HRT:
Hormone receptor status:
Breast cancer subtype in relation to parental cancer diagnosis status
Father with cancer, n = 297
Mother with cancer, n = 328
Father with cancer, n = 297
Mother with cancer, excluding breast cancer, n = 245
Risk factors related to lobular breast cancer
No family history of bc
Father with cancer
Lobular breast cancer in relation to first degree relatives
No breast cancer in 1st degree relatives
Cancer diagnoses in fathers stratified based on histological subtype of breast cancer
Lower GI-tract cancer
Other cancer diagnoses
Cancer diagnoses in the father related to lobular and ductal breast cancer
Father with prostate cancer, N = 1676
Father with cancer, not prostate cancer, N = 1597
Ductal cancer y/n
Lobular cancer y/n
Other cancers y/n
Father with prostate cancer, age at diagnosis > 60, N = 677
Father with prostate cancer, age at diagnosis < 60, N = 983
Ductal cancer y/n
Lobular cancer y/n
Other cancers y/n
Family history of breast cancer
Fathers age at daughter's birth
Fathers age at cancer diagnosis
Daughter's age at bc diagnosis
To eliminate the possibility that the paternal side had an increase of both cancer diagnoses in general and/or breast cancer in particular, compared to the maternal side, both the parents of the father and the mother were studied in all lobular breast cancer patients. On the paternal side 5 grandfathers and 13 grandmothers were diagnosed with cancer, and on the maternal side 4 grandfathers and 12 grandmothers were diagnosed with cancer. There were 5 maternal and 4 paternal grandmothers diagnosed with breast cancer. A binomial test was performed on these data and no significant difference was noted (data not shown).
Our data suggest a new familial pattern in patients with lobular breast cancer, demonstrating an association between lobular breast cancer and cancer in the father. Non-BRCA1/2 high risk breast cancer families have previously been associated with prostate cancer reported by Loman et al. . The study by Loman et al. was not made with pure lobular breast cancer, rather breast cancer in general. Associations between breast cancer and prostate cancer effects have been reported in three other studies as well [16–18], however no subdivision based on histopathologic breast cancer subtype was made. In a study by Rawal et al.  no association between prostate cancer and breast cancer was found. Neither of previous studies did subdivide their data based on histopathological types which could explain why they did not identify an association similar to ours.
It is clear that the association between a father with cancer and lobular breast cancer is not affected by a mother diagnosed with breast cancer, since there was no change in the results when removing cases with breast cancer diagnoses. Also, no interaction between the father and mother with cancer was found. Since the model was adjusted for ever-use of HRT, which is associated with an increased risk of lobular breast cancer , and number of children the likelihood that the finding is dependent on these factors seems unlikely. However, the power of the study was small because of the small sample size. Adding that to the fact that it is an exploratory study, the results need to be validated in an independent cohort.
The median age at diagnosis of the fathers of the lobular breast cancer patient was close to the median age at diagnosis for men in Sweden, which was approximately 75 years old in 2009 . Several of the fathers were born in the middle or late nineteenth century and if they were diagnosed with cancer at an early age they were not registered. These results are therefore biased due to the fact that information regarding cancer diagnosis in those fathers diagnosed at a younger age could not be confirmed since the Swedish tumor registry was not started until 1958.
Our data indicates that different tumor types of tumors in the father are associated with lobular breast cancer in the daughter. The theory that there might be a genetic cause is strengthened by the fact that it was the younger lobular breast cancer patients that had an increased risk of having a father with prostate cancer, compared to the other histopathologic breast cancer subtypes. Genetically caused breast cancer tends to present earlier than sporadic ones . However, the loss of statistical significance in the older patient group could be due to the sample size, which was smaller in the older patient group. It is important to remember that the association between lobular breast cancer and having a father diagnosed with cancer remained significant even when removing cases with a father diagnosed with prostate cancer. Indicating that this phenomenon is not connected to prostate cancer exclusively and that the remaining diagnoses that were more common amongst fathers of lobular breast cancer patients, such as leukemia, sarcoma and lower GI-tract cancer may be involved as well. In some families, sarcoma and breast cancer is associated with the Li-Fraumeni syndrome. However, none of our families fulfill the criteria for either Li-Fraumeni, or Li-Fraumeni like syndrome. That together with the age at onset of our patients strongly indicate that this is not connected with the Li-Fraumeni syndrome, in which the cancer usually presents at a much earlier age [22, 23]. Therefore, the task remains to determine if our finding is due to chance or represents a new syndrome.
There was no difference in cancer diagnoses in second and third degree relatives on the paternal or maternal side of the lobular breast cancer cases indicating that the association is not connected to an imbalance in number of cancer diagnoses on the paternal side. It also indicates that it may only be related to the father, or inherited from the father.
There are several possible theories explaining this phenomenon; one could be imprinting. In that case it could mean that the gene or polymorphism was maternally imprinted and therefore only the father's allele would be expressed, and predispose for cancer in men and breast cancer in their daughters. A recent study by Kong et al.  found a region at 11p15 with a paternal inheritance associated with breast cancer, which further supports the possibility of allelic imprinting or a peculiar inheritance involving males with cancer and females developing breast cancer. Another possibility could be copy number variation which, when placed in a gene beneficial for cancer development could predispose for cancer in men and breast cancer in women. A third possible explanation could be that it is due to common recessive haplotypes. Which in a heterozygote state predisposes for cancer in men but not women, and in a homozygote state predisposes for breast cancer in women. A fourth explanation could be that it is due to uniparental disomy (UPD) where both alleles, in this case, would be inherited from the father. However, the incidence of UPD has been estimated to be 1/80 000 births , which makes this hypothesis rather unlikely since we have several cases of patients with a father with cancer and are nowhere near a rate of 1/80 000.
Patients are referred to the Department of Oncology from the Southern Health Care Region in a population based setting. Since Skåne University Hospital, Lund is responsible for radio- and chemotherapy in the southern health care region of Sweden. The present clinical material was slightly younger at diagnosis compared to the median age at diagnosis in the southern health care region of Sweden. This is most likely because some older cases and cases only operated without adjuvant therapy (stage I) may not be referred to the Oncology clinic of Skåne University Hospital, Lund. Overall we receive around 60% of all breast cancer cases for therapy. Therefore our results may not fully be applicable to stage I or older patients. Bias in patient selection, except for the slightly younger population, as well as chance, seems unlikely. The material was collected under a long time period, reducing the possibility that it was a certain branch of the population included. The material was collected for research purposes, and the questionnaire was filled out by the physician in a structured interview, reducing the possibilities for different types of biases. We decided not to correct for multiple testing since this is an exploratory study . The findings in the present study need to be validated in an independent material.
Our study has identified a possible father-daughter inheritance pattern in lobular breast cancer, independent of previous family history of breast cancer. These findings need to be validated in other materials in order to later elucidate the possible mechanism behind the association.
The study has been supported by grants from the Swedish Cancer Society, The Swedish Research Council, The Hospital Funds of Skåne University Hospital, Lund, and Regional Research Funds in Skåne.
- Reeves GK, Pirie K, Green J, Bull D, Beral V, Million Women Study C: Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009, 100 (3): 538-544. 10.1038/sj.bjc.6604853.View ArticlePubMedPubMed CentralGoogle Scholar
- Zanetti-Dallenbach RA, Krause EM, Lapaire O, Gueth U, Holzgreve W, Wight E: Impact of hormone replacement therapy on the histologic subtype of breast cancer. Arch Gynecol Obstet. 2008, 278 (5): 443-449. 10.1007/s00404-008-0613-8.View ArticlePubMedGoogle Scholar
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266 (5182): 66-71. 10.1126/science.7545954.View ArticlePubMedGoogle Scholar
- Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378 (6559): 789-792. 10.1038/378789a0.View ArticlePubMedGoogle Scholar
- Lakhani SR: The pathology of hereditary breast cancer. Dis Markers. 1999, 15 (1-3): 113-114.View ArticlePubMedPubMed CentralGoogle Scholar
- Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004, 6 (3): R149-156. 10.1186/bcr767.View ArticlePubMedPubMed CentralGoogle Scholar
- Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008, 216 (2): 141-150. 10.1002/path.2407.View ArticlePubMedGoogle Scholar
- Li CI, Anderson BO, Daling JR, Moe RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003, 289 (11): 1421-1424. 10.1001/jama.289.11.1421.View ArticlePubMedGoogle Scholar
- Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DS: Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev. 19 (6): 1643-1654.Google Scholar
- Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Strom BL, Simon MS, Press MF, McDonald JA, et al: Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2006, 15 (5): 946-954. 10.1158/1055-9965.EPI-05-0881.View ArticlePubMedGoogle Scholar
- Allen-Brady K, Camp NJ, Ward JH, Cannon-Albright LA: Lobular breast cancer: excess familiality observed in the Utah Population Database. Int J Cancer. 2005, 117 (4): 655-661. 10.1002/ijc.21236.View ArticlePubMedGoogle Scholar
- Lorenzo Bermejo J, Hemminki K: Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer. 2004, 109 (3): 430-435. 10.1002/ijc.11713.View ArticlePubMedGoogle Scholar
- Kaurah P, Huntsman DG: Hereditary Diffuse Gastric Cancer. GeneReviews. Edited by: Pagon RA, Bird TD, Dolan CR, Stephens K. 1993, Seattle (WA)Google Scholar
- Ellberg C, Jonsson G, Olsson H: Can a phenotype for recessive inheritance in breast cancer be defined?. Familial Cancer. 2010, 9 (4): 525-530. 10.1007/s10689-010-9355-4.View ArticlePubMedGoogle Scholar
- Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H: Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res. 2003, 5 (6): R175-186. 10.1186/bcr632.View ArticlePubMedPubMed CentralGoogle Scholar
- Hemminki K, Chen B: Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. Prostate. 2005, 65 (2): 188-194. 10.1002/pros.20284.View ArticlePubMedGoogle Scholar
- Zeegers MP, Schouten LJ, Goldbohm RA, van den Brandt PA: A compendium of familial relative risks of cancer among first degree relatives: a population-based study. Int J Cancer. 2008, 123 (7): 1664-1673. 10.1002/ijc.23615.View ArticlePubMedGoogle Scholar
- Valeri A, Fournier G, Morin V, Morin JF, Drelon E, Mangin P, Teillac P, Berthon P, Cussenot O: Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer. 2000, 86 (6): 883-887. 10.1002/(SICI)1097-0215(20000615)86:6<883::AID-IJC20>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Rawal R, Bertelsen L, Olsen JH: Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer. Eur J Cancer. 2006, 42 (17): 3034-3040. 10.1016/j.ejca.2006.04.025.View ArticlePubMedGoogle Scholar
- National Board of Health S: Cancer incidence in Sweden 2009 = Cancerförekomst i Sverige 2009. 2010, Stockholm: The National Board of Health in SwedenGoogle Scholar
- Hyder SM, Nawaz Z, Chiappetta C, Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 2000, 60 (12): 3183-3190.PubMedGoogle Scholar
- Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P: Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010, 22 (1): 64-69. 10.1097/CCO.0b013e328333bf00.View ArticlePubMedGoogle Scholar
- Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Research. 1988, 48 (18): 5358-5362.PubMedGoogle Scholar
- Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S, Jonasdottir A, Sigurdsson A, Kristinsson KT, Frigge ML, et al: Parental origin of sequence variants associated with complex diseases. Nature. 2009, 462 (7275): 868-874. 10.1038/nature08625.View ArticlePubMedPubMed CentralGoogle Scholar
- Robinson WP: Mechanisms leading to uniparental disomy and their clinical consequences. Bioessays. 2000, 22 (5): 452-459. 10.1002/(SICI)1521-1878(200005)22:5<452::AID-BIES7>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Bender R, Lange S: Adjusting for multiple testing--when and how?. J Clin Epidemiol. 2001, 54 (4): 343-349. 10.1016/S0895-4356(00)00314-0.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/11/497/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.